C OSBORNE to Animals
This is a "connection" page, showing publications C OSBORNE has written about Animals.
Connection Strength
0.228
-
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004 Mar; 90 Suppl 1:S2-6.
Score: 0.012
-
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):331S-6S.
Score: 0.012
-
Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. Mol Endocrinol. 2003 Aug; 17(8):1543-54.
Score: 0.011
-
Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4338s-4342s; discussion 4411s-4412s.
Score: 0.010
-
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34.
Score: 0.010
-
Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol. 2000 Sep; 18(17):3172-86.
Score: 0.010
-
Phylogenetic patterns and phenotypic profiles of the species of plants and mammals farmed for food. Nat Ecol Evol. 2018 11; 2(11):1808-1817.
Score: 0.008
-
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995 May 17; 87(10):746-50.
Score: 0.007
-
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3.
Score: 0.006
-
Mechanisms of tamoxifen resistance. Breast Cancer Res Treat. 1994; 32(1):49-55.
Score: 0.006
-
Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res Treat. 1994; 32(1):97-103.
Score: 0.006
-
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol. 1994; 34(2):89-95.
Score: 0.006
-
Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol. 1993 Dec; 47(1-6):83-9.
Score: 0.006
-
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992; 24(2):85-95.
Score: 0.005
-
Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst. 1991 Oct 16; 83(20):1477-82.
Score: 0.005
-
Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest. 1989 Nov; 84(5):1418-23.
Score: 0.005
-
Antitumor activity and murine pharmacokinetics of parenteral acronycine. Cancer Res. 1989 Jan 15; 49(2):340-4.
Score: 0.004
-
Tumor and serum tamoxifen concentrations in the athymic nude mouse. Cancer Chemother Pharmacol. 1989; 23(2):68-70.
Score: 0.004
-
Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse model. Breast Cancer Res Treat. 1988 Jul; 11(3):211-9.
Score: 0.004
-
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008 Feb 01; 68(3):826-33.
Score: 0.004
-
Endocrine therapy of human breast cancer grown in nude mice. Breast Cancer Res Treat. 1987 Dec; 10(3):229-42.
Score: 0.004
-
Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol. 1987 Aug; 23(8):1189-96.
Score: 0.004
-
Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat. 1987; 9(2):111-21.
Score: 0.004
-
Serum tamoxifen concentrations in the athymic nude mouse after three methods of administration. Cancer Chemother Pharmacol. 1987; 20(4):316-8.
Score: 0.004
-
Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell. 2006 Dec; 10(6):487-99.
Score: 0.004
-
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006 Aug 15; 66(16):8266-73.
Score: 0.004
-
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat. 2006 Aug; 98(3):315-27.
Score: 0.004
-
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005 Apr 10; 23(11):2469-76.
Score: 0.003
-
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985 Feb; 45(2):584-90.
Score: 0.003
-
Evaluation of the association between initial proteinuria and morbidity rate or death in dogs with naturally occurring chronic renal failure. J Am Vet Med Assoc. 2005 Feb 01; 226(3):393-400.
Score: 0.003
-
Bisantrene, biological and clinical effects. Cancer Treat Rev. 1984 Dec; 11(4):285-8.
Score: 0.003
-
Perturbation by insulin of human breast cancer cell cycle kinetics. Cancer Res. 1984 Aug; 44(8):3570-5.
Score: 0.003
-
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004 Jun 16; 96(12):926-35.
Score: 0.003
-
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33.
Score: 0.003
-
Enhanced gene expression in breast cancer cells in vitro and tumors in vivo. Mol Ther. 2002 Dec; 6(6):783-92.
Score: 0.003
-
Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 Oct 31; 21(50):7680-9.
Score: 0.003
-
HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer. Clin Cancer Res. 2000 Sep; 6(9):3788-96.
Score: 0.002
-
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer. 2000 Aug 15; 89(4):817-25.
Score: 0.002
-
Epidermal growth factor stimulation of human breast cancer cells in culture. Cancer Res. 1980 Jul; 40(7):2361-6.
Score: 0.002
-
Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol Endocrinol. 2000 Mar; 14(3):369-81.
Score: 0.002
-
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999 May; 13(5):787-96.
Score: 0.002
-
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst. 1999 Mar 03; 91(5):453-9.
Score: 0.002
-
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):2920-5.
Score: 0.002
-
Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res. 1997 Dec 15; 57(24):5505-8.
Score: 0.002
-
Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Res. 1997 Sep 01; 57(17):3723-7.
Score: 0.002
-
Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer. 1997 Jun; 33(7):1108-13.
Score: 0.002
-
Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat. 1995 Mar; 33(3):199-207.
Score: 0.002
-
The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J. 1994 Mar 15; 13(6):1331-40.
Score: 0.002
-
Effect of methemoglobin on in vivo RBC lipid peroxidation. Aerosp Med. 1973 Jan; 44(1):63-7.
Score: 0.001
-
Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol. 1992 Jun; 10(6):990-4.
Score: 0.001
-
Effects of hyperoxia on white blood cells. I. In vivo changes in the total white blood cell counts of normal rats. Aerosp Med. 1970 Oct; 41(10):1176-9.
Score: 0.001
-
Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells. Oncogene. 1989 Aug; 4(8):979-84.
Score: 0.001
-
Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. Science. 1983 Sep 23; 221(4617):1292-4.
Score: 0.001
-
Breast cancer mortality and diet in the United States. Cancer Res. 1979 Sep; 39(9):3628-37.
Score: 0.001
-
In vitro model systems for the study of hormone-dependent human breast cancer. N Engl J Med. 1977 Jan 20; 296(3):154-9.
Score: 0.000